Key points are not available for this paper at this time.
The main point about excess in the pharmaceutical industry is how much there is of it. Here I can touch on only a few specifics about this altogether over-the-top business. !Figure1 Figure. Photo by: Earthlore Although the pharmaceutical industry claims to be a high-risk business,
Marcia Angell (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: